PET/CT imaging of gastrointestinal stromal tumor with calcified peritoneal implants after imatinib therapy

Clinical Nuclear Medicine

Volumn 33, Issue 12, 2008, Pages 864-865

  Eslamy, Hedieh K ^a   Quon, Andrew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

F 18 fluorodeoxyglucose; Gastrointestinal stromal tumor; Imatinib; PET CT; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DISTRIBUTION; TREATMENT RESPONSE; TUMOR CALCINOSIS; UNSPECIFIED SIDE EFFECT; CALCINOSIS; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; PERITONEUM; PROSTHESES AND ORTHOSES; SCINTISCANNING;

ANTINEOPLASTIC AGENTS; CALCINOSIS; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MIDDLE AGED; PERITONEUM; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROSTHESES AND IMPLANTS; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 58749109018     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31818bf15c     Document Type: Article

References (12)

1. Lau S, Tam KF, Kam CK, et al. Imaging of gastrointestinal stromal tumour (GIST). Clin Radiol. 2004;59:487-498.
2. Sandrasegaran K, Rajesh A, Rushing DA, et al. Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol. 2005;15:1407-1414.
3. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003; 39:2012-2020.
4. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun. 2004;25:433-438.
5. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21; Erratum in: J Nucl Med. 2004 Nov;45:1803.
6. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183:1619-1628.
7. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357-365.
8. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32:153-162.
9. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with meta-static gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-1759.
10. Rosai J. Gastrointestinal tract. In: Rosai J, Ewing J, eds. Ackerman's Surgical Pathology. St Louis, MO: Mosby Year-Book; 1996:645-6932.
11. Ponsaing LG, Hansen MB. Therapeutic procedures for submucosal tumors in the gastrointestinal tract. World J Gastroenterol. 2007;13: 3316-3322.
12. Gleevec prescribing information. Available at: http://www.gleevec.com/ hcp/index.jsp. Accessed on September 27, 2007.